PBS listings take the slow lane

Posted 22 April 2024 AM

Pharmaceutical reimbursement processes are going backwards, with the time to funding for 2022-23 taking longer than the previous year.

The Stage 1 and 2 PBS Process Improvements Metrics Report measures metrics that align with the main objectives of the Strategic Agreement, with a focus on improving HTA processes to facilitate earlier patient access to medicines. The report for the period 2022-23 reveals that it took longer than the previous year for medicines to be listed on the PBS once they received a recommendation from PBAC.

To see the whole article, please login